679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This comprehensive network meta-analysis provides crucial evidence that Tirzepatide may be the most efficacious pharmacological option for weight management in individuals with obesity who do not have Type 2 Diabetes.…
This comprehensive meta-analysis solidifies the role of GLP-1 receptor agonists as highly effective pharmacological interventions for obesity management, providing strong evidence for their widespread clinical adoptio…
This study provides compelling real-world evidence that Tirzepatide, a dual GLP-1 and GIP receptor agonist, may offer superior neuroprotection compared to semaglutide (a GLP-1 receptor agonist) in patients with type 2…
This comprehensive scoping review provides compelling evidence that GLP-1 receptor agonists and Tirzepatide are not just effective for glycemic control and weight management, but also offer substantial and consistent …
This case report highlights a critical safety concern for patients on tirzepatide and SGLT-2 inhibitors, emphasizing the importance of patient education regarding 'sick-day rules.' The finding that these agents can be…
This joint guidance statement represents a significant step forward in standardizing and optimizing the pharmacological management of overweight and obesity in the United States. By providing clear, evidence-based rec…
This comprehensive review provides crucial guidance for clinicians and patients regarding the safe and effective use of GLP-1 RAs in individuals of reproductive age. It underscores the critical need for thorough couns…
This real-world evidence strongly suggests that Tirzepatide may offer significant cardiovascular protection beyond its established metabolic benefits, even in patients without diabetes. The observed reduction in recur…
This study highlights a critical concern: while GLP-1 receptor agonists are highly effective for weight loss, the potential for significant lean muscle mass loss needs careful consideration. Preserving muscle is vital…
This 2026 Update provides crucial, up-to-date, and evidence-based recommendations that will significantly impact the clinical management of MASLD and MASH globally. By clearly outlining the efficacy of various pharmac…
This post-hoc analysis highlights the critical importance of early treatment response as a predictor of overall success with tirzepatide and semaglutide for obesity. The findings suggest that monitoring early weight l…
The profound influence of social media on public health discourse and patient behavior is a critical concern, particularly for highly sought-after medications like GLP-1 RAs. This research underscores an urgent need f…
This systematic review highlights a novel and potentially impactful therapeutic avenue for patients suffering from Hidradenitis Suppurativa, particularly those with underlying metabolic comorbidities. Repurposing exis…
This comprehensive network meta-analysis provides crucial evidence for the comparative effectiveness of GLP-1 receptor and dual agonists in managing obesity. The findings strongly suggest that tirzepatide offers the m…
This review highlights a critical gap in our understanding of optimal T2DM management during pregnancy, particularly concerning newer, highly effective antidiabetic agents. The limited evidence for novel therapies mea…
This study highlights that not all GLP-1 RAs are interchangeable regarding their safety profiles, providing crucial insights for personalized medicine. Clinicians can use this real-world evidence to make more informed…
This review highlights the significant challenge of maintaining weight loss and cardiometabolic improvements after discontinuing GLP-1 RA therapy, emphasizing that obesity is a chronic disease requiring long-term mana…
This study provides compelling real-world evidence suggesting tirzepatide offers superior cardiovascular protection compared to semaglutide in non-diabetic individuals with obesity. These findings are crucial for guid…
This comprehensive analysis provides crucial real-world insights into the safety profile of tirzepatide, confirming and quantifying the prevalence of its associated gastrointestinal adverse events. The identification …
This comprehensive review provides crucial insights into the safety profile of tirzepatide for patients who stand to benefit most from its metabolic effects but also carry significant cardiovascular risk. The finding …
This comprehensive review significantly advances our understanding of the multifaceted actions of GLP-1 Receptor Agonists, extending beyond their well-known direct metabolic effects. The identified interplay between G…
These findings are crucial for informing prescribing practices and patient monitoring for individuals on GLP-1 RAs, especially those with pre-existing diabetic eye disease. Given the widespread and increasing use of t…
This study provides crucial real-world insights into the safety profile of GLP-1 RAs, emphasizing the importance of monitoring for psychiatric adverse events beyond controlled clinical trial settings. The identificati…
This comprehensive, exposure-adjusted analysis provides robust evidence supporting the superiority of GLP-1 and GLP-1/GIP receptor agonists for managing obesity and type 2 diabetes. The findings reinforce their positi…
This study provides compelling real-world evidence that Tirzepatide effectively promotes significant additional weight loss even in patients who have already achieved initial weight reduction. This reinforces its util…
This study provides compelling evidence that tirzepatide offers superior cardiorenal protection compared to dulaglutide, a well-established GLP-1 RA, in patients with type 2 diabetes and cardiovascular disease. This s…
This case highlights a potentially rare but serious adverse effect of Tirzepatide, warranting increased awareness among clinicians. Recognizing drug-induced ITP is crucial for timely discontinuation of the offending a…
This study provides compelling evidence supporting the clinical benefit of switching patients with inadequately controlled Type 2 Diabetes from dulaglutide to tirzepatide. The consistent efficacy observed across diver…
This real-world evidence suggests that GLP-1 and dual agonists may offer a critical additional benefit by preventing the onset of sleep apnea, a condition with significant long-term health consequences. This could tra…
This comprehensive review highlights the significant potential of incretin-mimetic drugs as a strategy for cancer prevention, especially in populations at high risk due to obesity and metabolic disorders. The findings…
These findings underscore the critical importance of recognizing and addressing racial disparities in treatment efficacy for obesity management. Understanding these differences in GLP-1RA response is crucial for devel…
This review underscores Tirzepatide's potential as a multifaceted therapeutic agent for a range of metabolic disorders, not just diabetes and obesity. Its broad impact on hepatic, cardiovascular, and renal health sugg…
This case report highlights the potential for Tirzepatide to address alcohol use disorder in patients with significant metabolic comorbidities. Given the high prevalence of type 2 diabetes and obesity in individuals w…
This comprehensive review is critical for guiding clinicians and policymakers in India to implement evidence-based and effective obesity management strategies. By synthesizing the latest data and expert consensus from…
The findings underscore the critical role of multi-targeted approaches in effectively treating the complex pathology of MASLD. This comprehensive overview provides a roadmap for future drug development, emphasizing th…
This review underscores the rapid and profound evolution of obesity pharmacotherapy, offering unprecedented hope for patients struggling with chronic weight management. The development of highly effective drugs like G…
This hypothetical study strongly suggests that integrating resistance exercise with incretin-based weight loss pharmacotherapy is critical for optimizing body composition, mitigating sarcopenia (age-related muscle los…
This review underscores the transformative potential of GIP receptor-based therapies as a powerful new class of drugs for obesity management. The impressive weight loss and metabolic improvements observed suggest thes…
This review significantly advances our understanding of the multifaceted nature of obesity, providing a robust framework for developing more effective and personalized treatments. The detailed exploration of molecular…
This comprehensive meta-analysis solidifies retatrutide's position as a highly effective treatment for obesity and related metabolic disorders, offering a robust evidence base for its broad therapeutic potential. The …
This review is crucial for clinicians and researchers, underscoring the need for a paradigm shift in Type 2 Diabetes (T2D) management from a purely pharmacological approach to a holistic, integrated model. It emphasiz…
This systematic review provides compelling evidence that incretin therapies, especially GLP-1 receptor agonists, are not merely glucose-lowering agents but also offer significant cardiovascular protection for individu…
Preserving fat-free mass during weight loss is paramount for maintaining metabolic health, physical function, and reducing frailty, especially in older adults. This review underscores the urgent need for anti-obesity …
This review underscores a transformative era in obesity management, moving beyond modest weight loss to therapies offering substantial and sustained reductions. The comprehensive overview provided by the authors is cr…
This systematic review underscores the rapid evolution of pharmacotherapy for obesity, offering unprecedented hope for effective and substantial weight management. The identified therapies, particularly multi-agonist …